• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 5. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Tetrahydroisoquinolines Tetrahydroisoquinolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Tetrahydroisoquinolines

Chemical Profile of 4,7-Dimethyl-1,2,3,4-tetrahydroisoquinoline (CAS No. 1267865-80-4)

4,7-Dimethyl-1,2,3,4-tetrahydroisoquinoline, identified by its Chemical Abstracts Service number CAS No. 1267865-80-4, is a heterocyclic organic compound belonging to the tetrahydroisoquinoline class. This compound has garnered significant attention in the field of medicinal chemistry due to its structural similarity to several bioactive alkaloids and its potential pharmacological applications. The presence of two methyl groups at the 4- and 7-positions enhances its molecular complexity and may contribute to unique interactions with biological targets.

The tetrahydroisoquinoline scaffold is a privileged structure in drug discovery, known for its role in various pharmacological activities ranging from CNS modulation to cardiovascular effects. Compounds within this class have been extensively studied for their potential as intermediates in the synthesis of therapeutic agents. The specific substitution pattern of 4,7-Dimethyl-1,2,3,4-tetrahydroisoquinoline makes it an intriguing candidate for further investigation into its biological properties and synthetic utility.

Recent advancements in computational chemistry and molecular modeling have enabled a deeper understanding of the interactions between tetrahydroisoquinoline derivatives and biological macromolecules. Studies have highlighted the importance of the aromaticity and hydrogen bonding capabilities of this scaffold in modulating receptor binding affinity. The methyl substituents in 4,7-Dimethyl-1,2,3,4-tetrahydroisoquinoline may play a crucial role in fine-tuning these interactions, potentially leading to novel pharmacophores for drug development.

In the context of medicinal chemistry research, 4,7-Dimethyl-1,2,3,4-tetrahydroisoquinoline serves as a valuable building block for designing analogs with enhanced potency and selectivity. The compound’s ability to undergo functionalization at multiple positions allows chemists to explore diverse structural modifications. For instance, introducing additional substituents or altering the substitution pattern could lead to derivatives with improved pharmacokinetic profiles or altered target specificity.

One of the most promising areas of research involving tetrahydroisoquinoline derivatives is their potential as precursors for bioactive molecules targeting neurological disorders. The structural motif is found in several natural products known for their effects on neurotransmitter systems. 4,7-Dimethyl-1,2,3,4-tetrahydroisoquinoline, with its optimized substitution pattern, could be a key intermediate in synthesizing new agents for conditions such as depression or Parkinson’s disease. Ongoing studies are exploring its derivatives as modulators of monoamine oxidase (MAO) enzymes and other relevant targets.

The synthesis of 4,7-Dimethyl-1,2,3,4-tetrahydroisoquinoline has been optimized through various methodologies to ensure high yield and purity. Traditional approaches involve palladium-catalyzed cross-coupling reactions and cyclization steps that construct the core tetrahydroisoquinoline ring system. Advances in synthetic techniques have enabled more efficient routes, reducing the number of steps and byproducts while maintaining scalability for industrial applications.

From a regulatory perspective, compounds like 4,7-Dimethyl-1,2,3,4-tetrahydroisoquinoline are subject to guidelines that ensure safe handling and proper documentation during research and development. While not classified as hazardous or controlled substances under current regulations, adherence to good laboratory practices (GLP) is essential when working with organic intermediates. This includes proper storage conditions and waste disposal protocols to minimize environmental impact.

The growing interest in natural product-inspired drug discovery has spurred investigations into synthetic pathways that mimic biosynthetic routes. By leveraging insights from enzymatic processes that produce tetrahydroisoquinoline alkaloids in plants and animals, 4 ,7 -Dimethyl -1 ,2 ,3 ,4 -tetrahydroisoquinoline can be synthesized more sustainably. Such biologically inspired approaches not only enhance efficiency but also align with green chemistry principles by reducing reliance on harsh reagents or energy-intensive processes.

In conclusion, 4 ,7 -Dimethyl -1 ,2 ,3 ,4 -tetrahydroisoquinoline (CAS No . 1267865 -80 -4) represents a significant compound in medicinal chemistry with broad applications across multiple therapeutic areas . Its unique structural features make it an excellent candidate for further exploration as both a starting material and an active pharmaceutical ingredient . Continued research into its biological activity will likely uncover new opportunities for treating complex diseases while advancing synthetic methodologies .

• 42923-76-2(6-Methyl-1,2,3,4-tetrahydroisoquinoline)
• 129961-74-6(8-Methyl-1,2,3,4-tetrahydroisoquinoline)
• 91-21-4(1,2,3,4-Tetrahydroisoquinoline)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)